Compare Inovio Pharmaceuticals Inc (INO) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while abrdn Physical Palladium Shares ETF trades at $24.86. The key difference: abrdn Physical Palladium Shares ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PALL | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.87 | $37.18 |
52-Week Low | $0.66 | $19.96 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $25.15, showing minimal daily movement with a 0.16% gain. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. The ETF recently underwent a 1:5 stock split effective May 18, 2026, adjusting share structure while maintaining exposure to physical palladium.
PALL offers exposure to palladium's supply-demand dynamics amid current price weakness, with analysts viewing the 47% decline from January 2026 highs as a potential buying opportunity. Key risks include Federal Reserve policy uncertainty and industrial demand fluctuations. The ETF's physical backing provides direct commodity exposure, though palladium's volatility requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
